New combo shrinks lung tumors before surgery in phase 2 trial

NCT ID NCT06449313

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 25 times

Summary

This study tests whether giving chemotherapy plus an immunotherapy drug (cemiplimab) before surgery can help people with stage 3 non-small cell lung cancer that has spread to certain lymph nodes. About 21 adults will receive four cycles of the combination, then have surgery to remove the tumor. After surgery, they may get radiation and will continue cemiplimab for a year. The main goal is to see if the cancer disappears completely in the removed tissue.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER (STAGE III) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Lombardi Comprehensive Cancer Center, Georgetown University

    RECRUITING

    Washington D.C., District of Columbia, 20007, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • UVA Comprehensive Cancer Center

    RECRUITING

    Charlottesville, Virginia, 22908, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Washington University School of Medicine-Sitemen Cancer Center

    RECRUITING

    St Louis, Missouri, 63110, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.